Key facts
- This page summarizes Robert B. Bazemore's Form 4 filing for Akari Therapeutics Plc (AKTX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Mar 2025, 17:00.
Robert B. Bazemore - 20 Mar 2025 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)
- Reporting relationship
- Director
- Issuer ticker
- AKTX
- Reported as of
- 20 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Mar 2025, 17:00:15 UTC
- Prior SEC filing
- 10 Mar 2025
- Next SEC filing
- 23 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Torsten Hombeck, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert B. Bazemore filed Form 4 for Akari Therapeutics Plc (AKTX) on 24 Mar 2025.
Change
- Previous filing in this sequence was filed on 10 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKTX
holding
American Depositary Shares representing Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 44,642
- Date
- 20 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +175,000
- Change %
- Price
- $0.000000
- Shares after
- 175,000
- Date
- 20 Mar 2025
- Ownership
- Direct
- Underlying class
- American Depositary Shares representing Ordinary Shares
- Underlying amount
- 175,000
- Exercise price
- $1.50
- Footnotes
- F1, F2
AKTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +225,000
- Change %
- Price
- $0.000000
- Shares after
- 225,000
- Date
- 20 Mar 2025
- Ownership
- Direct
- Underlying class
- American Depositary Shares representing Ordinary Shares
- Underlying amount
- 225,000
- Exercise price
- $1.50
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer.
Footnote F2
The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer.
Footnote F3
The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. Subject to the Reporting Person's continued service with the Issuer and shareholder approval covering the issuance of the ADS underlying this stock option, this option shall vest (i) 25% on the grant date (ii) 25% on December 31, 2025 and (iii) the remaining 50% shall vest ratably on a monthly basis over the 24 month period thereafter.